y Celltech Group plc, of London, has signed two manufacturingagreements worth up to L1.85 million sterling (U.S. $2.78 million) withBristol-Myers Squibb, of New York, and the Swedish company ABAstra for the contract production of therapeutic monoclonal antibodiesand other genetically engineered proteins.y A viral neutralizing factor developed by Embrex Inc.(NASDAQ:EMBX, EMBXW) of Research Triangle Park, N.C., that isincorporated into a vaccine complex developed by Sanofi AnimalHealth Inc., of Overland Park, Kansas, will begin field trials with newproduction lots after receiving the go ahead from the U.S. Departmentof Agriculture. The Infectious Bursal Disease or Gumboro vaccine isinjected into eggs using Embrex's Innovoject system.y Arcturus Pharmaceutical Corp., of Woburn, Mass., and TransCanaDerm Inc., of St. Laurent, Quebec, have signed an agreement todevelop and commercialize in Canada dermatologic products underdevelopment by Arcturus. Trans CanaDerm will provide fundingsupport for initial development work by Arcturus as for Phase IIIclinical trials in Canada. The company will also make an equityinvestment in Arcturus, a developer of determatologic products.
(c) 1997 American Health Consultants. All rights reserved.